Business Wire

80% of Companies Are Confident They’re Ready to Meet 2026 e-Invoicing Mandates According to New Generix Survey

1.10.2025 09:00:00 CEST | Business Wire | Press Release

Share

Generix, a global business software company offering an expansive portfolio of SaaS solutions for supply chain, finance, commerce, and B2B integration, today announces the results of their 6th annual “Tax Reform and Electronic Invoicing Barometer,” a survey of more than 200 French decision makers from large and mid-sized companies on their e-invoicing practices and preparation for the 2026/2027 tax reform.

According to the study's results, 80% of companies are confident they will be able to meet the requirement of having 100% of invoices in a structured electronic format by the September 1, 2026 deadline for large and mid-sized companies. Better still, 58% of these companies are ready to start processing invoices electronically in 2025.

Since the 2024 barometer, the reform ecosystem has rapidly evolved, with a sharp increase in Approved Platforms (from 56 to 107), the implementation of beta-testing pilots, the launch of PPF, the publication of technical standards and guides, and the launch of governance bodies like the AFNOR commission and the PEPPOL authority.

With 34% of respondents estimating that the overall cost of the project will be over €1 million, almost all (99%) of respondents are already seeing the added benefits of automation, beyond regulations compliance.

“With such high adoption numbers, companies are already able to realize several benefits as positive consequences of compliance. Within the constraints of the reform, they are already seeing profit opportunities,” explains Christophe Viry, Product & Marketing Director at Generix. “Regulatory compliance requires the processing of structured data and the automation of incoming and outgoing invoicing chains. We are already seeing this lead to tangible savings across the business.”

Over the past three years, the automation rankings have remained mostly unchanged and in fact, have increased in favor of automating invoicing processes.

  • Automation of inbound invoicing processes increased to 78%, compared to 46% in 2023
  • Automation of outbound invoicing processes is 73% in 2025, compared to 69% in 2023
  • Data reliability and the fight against errors and fraud increased to 62% in 2025, compared to 42% in 2023
  • Improvements in cash management increased from 38% to 60% between 2023 and 2025

For its part, in 2024, Generix obtained its registration numbers as an Approved Platform. This registration allows Generix to act as a trusted third party and operate on behalf of its clients to issue and receive electronic invoices, manage companies in the national directory, and collect e-reporting data for the administration.

With over 25 years of experience as an electronic invoicing operator, Generix aims to be the leading Approved Platform in terms of invoice volume and has already signed numerous contracts, representing a total volume of over 800 million invoices.

Methodology
Online survey, conducted by Exaegis in June 2025 on behalf of Generix, among 206 French decision-makers (financial directors, accounting directors, project directors, business directors, etc.) from large companies and mid-sized companies, in the Retail, Transport & Logistics, Services and Industry sectors.

About Generix
Generix is ​​a global SaaS company that helps businesses connect to each other to transform every digital connection into digital value. It offers a portfolio of cutting-edge, AI-powered cloud solutions and services to confidently drive the most critical digital business processes in supply chain, finance, and commerce. It also provides end-to-end B2B integration and collaboration solutions so businesses can fully operate on digital commerce networks. More than 900 Generix employees are dedicated to best serving more than 5,000 customers in over 60 countries. The company helps process more than 17 billion messages, prepare more than 600 million pallets, manage more than 800 million invoices, and manage more than 1 million transportation operations annually. Generix believes in the tremendous growth potential of the networked economy in a sustainable world. More information: www.generixgroup.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20250930114460/en/

Contacts

Media Inquiries:
Laurel Case
news@talesplash.com
+1 315-663-6780

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye